Pilot feasibility, acceptability, and tolerability of researcher-delivered apolipoprotein E ( APOE ) disclosure via videoconferencing in Australian adults at-risk of dementia
Journal of Alzheimer’s Disease · 2026-08 · 112 (3) · 1552-1565
DOI: 10.1177/13872877261459068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 18.06.2026. Verfasst von Emily Rosenich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Dementia, Apolipoproteins E, Videoconferencing, Disclosure. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Turner Institute for Brain and Mental Health, Monash University, National Health and Medical Research Council, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Background
In Australia, access to Alzheimer's disease (AD) therapeutics requires apolipoprotein E ( APOE ) genotype testing and disclosure, yet the feasibility, acceptability and tolerability of APOE disclosure in an Australian context remains unknown.
Objective
This pilot study evaluated a researcher-delivered, videoconferencing-based APOE disclosure protocol in cognitively unimpaired (CU) Australian adults with dementia family history.
Methods
The DISCLOSE- APOE protocol, informed by prior expert approaches and Australian consumer preferences, was piloted in fifteen CU adults aged 40–70 (8 ε4 carriers, 7 non-carriers). The protocol comprised 7 online sessions, including mood/suicide risk assessment, education, and psychological readiness evaluation. APOE genotype was disclosed 1:1 via videoconferencing using a standardized interaction procedure. Existing data and online questionnaires assessed participant characteristics and outcomes pre- and post-disclosure. Paired-samples t-tests examined within-group mood changes, and independent-samples t-tests compared post-disclosure test-/event-related distress between carriers and non-carriers.
Results
All participants (M age = 60.8 (±6.4), 60% female) completed the pilot, and no adverse events occurred. Baseline mood was equivalent across groups. Anxiety decreased post-disclosure in both ε4 carriers and non-carriers. Depressive symptoms increased slightly but not significantly in ε4 carriers and remained sub-threshold. Test-related distress was moderately higher in ε4 carriers post-disclosure.
Conclusions
Researcher-delivered and remote APOE disclosure via videoconferencing resulted in no attrition nor clinically-significant short-term psychological distress, with pilot data providing preliminary evidence of feasibility, acceptability and tolerability in this cohort. Findings will inform the development and implementation of culturally-appropriate and scalable APOE disclosure protocols in research and clinical settings to facilitate delivery of anti-Aβ therapies in Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Australia.
- Cogstate Ltd, Melbourne, Australia.
ORCID-Profile: Emily Rosenich, Lisa Bransby, Paul Maruff, Yen Ying Lim
Förderung
- Turner Institute for Brain and Mental Health, Monash University
- National Health and Medical Research Council
- Alzheimer's Association
Zitieren
APA
Rosenich, E., Chauhan, S., Haeusler, R., Keriakes, M., Cummins, H., Olver, H., Bransby, L., Maruff, P., & Lim, Y. Y. (2026). Pilot feasibility, acceptability, and tolerability of researcher-delivered apolipoprotein E ( APOE ) disclosure via videoconferencing in Australian adults at-risk of dementia. Journal of Alzheimer’s Disease, 112(3), 1552-1565. https://doi.org/10.1177/13872877261459068
Vancouver
Rosenich E, Chauhan S, Haeusler R, Keriakes M, Cummins H, Olver H, et al. Pilot feasibility, acceptability, and tolerability of researcher-delivered apolipoprotein E ( APOE ) disclosure via videoconferencing in Australian adults at-risk of dementia. Journal of Alzheimer’s Disease. 2026;112(3):1552-1565. doi:10.1177/13872877261459068
BibTeX
@article{Rosenich2026,
author = {Rosenich, Emily and Chauhan, Simran and Haeusler, Ruby and Keriakes, Mirette and Cummins, Hannah and Olver, Hannah and Bransby, Lisa and Maruff, Paul and Lim, Yen Ying},
title = {Pilot feasibility, acceptability, and tolerability of researcher-delivered apolipoprotein E ( APOE ) disclosure via videoconferencing in Australian adults at-risk of dementia},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
volume = {112},
number = {3},
pages = {1552--1565},
doi = {10.1177/13872877261459068}
}
EUVIMED